CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 185 enrolled
Drug / intervention
Xanamem™ +1 moredrug
Likely dose
Xanamem™ 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02727699
NCT02727699Phase 2Completed
CompareCT.gov

XanADu: A Phase II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of Xanamem™ in Subjects With Mild Dementia Due to Alzheimer's Disease (AD)

Actinogen Medical·interventional·Posted Apr 5, 2016·Updated Feb 3, 2025

In Brief

A Phase 2 clinical trial evaluating Xanamem™ and Placebo (for Xanamem™) for Dementia, Alzheimer Type. Completed, enrolled 185 participants across 25 sites in 3 countries.

Detailed Summary

This XanADu Phase II study in mild Alzheimer's Disease (AD) is to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's Disease. Subjects will be randomized to receive either 10mg once daily Xanamem or Placebo at a 1:1 ratio in a double-blinded fashion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDementia, Alzheimer Type
CountriesAustralia, United Kingdom, United States
CollaboratorsICON Clinical Research

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 5, 2016
Enrollment StartMar 23, 2017
Primary CompletionMar 15, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.2 years ago

Interventions

Xanamem™drug

Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343

Placebo (for Xanamem™)drug

Excipient blend capsules manufactured to mimic Xanamem™ capsules